FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria
Decision brief
Answer first · skim in under a minute
The FDA approved Immgolis and Immgolis Intri as the first interchangeable biosimilars to Janssen’s Simponi and Simponi Aria. The decision covers rheumatoid arthritis and ulcerative colitis and creates a new catalyst for BD teams and investors tracking golimumab competition.
FDA Approves First Biosimilars Interchangeable to Simponi and Simponi Aria: Immgolis and Immgolis Intri (golimumab-sldi) became the first interchangeable biosimilars to Janssen’s golimumab franchise for rheumatoid arthritis and ulcerative colitis indications listed by the agency.
Contents10 sections
Key Takeaways
- Immgolis is an interchangeable biosimilar to subcutaneous Simponi; Immgolis Intri is an interchangeable biosimilar to intravenous Simponi Aria.
- Both products use the nonproprietary name golimumab-sldi.
- FDA based approval on analytical similarity plus clinical pharmacology evidence, including PK similarity and immunogenicity for Immgolis versus Simponi.
- Interchangeability designation enables pharmacy-level substitution where state law allows.
What exactly did FDA approve?
FDA approved Immgolis (golimumab-sldi) as an interchangeable biosimilar biological product to Simponi (golimumab) and Immgolis Intri (golimumab-sldi) as an interchangeable biosimilar to Simponi Aria (golimumab).
The agency states these are the first biosimilars approved for Simponi and Simponi Aria, respectively, in its May 2026 FDA announcement.
How do the presentations differ?
Immgolis is given by subcutaneous injection from a single-dose prefilled syringe. Immgolis Intri is given as an intravenous infusion prepared from a single-dose vial. That presentation split mirrors the reference Simponi (SC) and Simponi Aria (IV) products.
- Reference SC product: Simponi (golimumab)
- Reference IV product: Simponi Aria (golimumab)
- Biosimilar nonproprietary name: golimumab-sldi for both
Which adult indications are covered?
FDA states Immgolis is approved for adult treatment indications currently approved for Simponi, including moderately to severely active rheumatoid arthritis and moderately to severely active ulcerative colitis among the listed uses. Immgolis Intri is approved for adult treatment indications currently approved for Simponi Aria, including rheumatoid arthritis settings described in the agency notice.
Teams should confirm the full labeled indication list on FDA Drugs@FDA when labeling PDFs are posted, rather than relying on secondary summaries.
What evidence supported biosimilarity and interchangeability?
FDA said approval rested on a comprehensive scientific review showing the products are highly similar to their reference products with no clinically meaningful differences. Multiple lots were compared across product quality attributes affecting structure and function.
A pharmacokinetic similarity study showed comparable exposure and immunogenicity results for subjects treated with Immgolis versus Simponi. The totality of evidence supported interchangeable biosimilar designations.
What remains open for commercialization and payers?
FDA approval is not the same as immediate U.S. availability. Launch timing, litigation with the reference sponsor, HCPCS coding, and formulary placement will determine uptake. Interchangeability does not override state pharmacy law or payer medical-policy edits.
Related NovaPharma coverage
- FDA Drug Approval: What Approval Means for Pharma Marketing and BD
- Europe Drug Prices Face Pressure as U.S. Benchmarking Tightens
- Rheumatoid arthritis disease hub
What does interchangeability change for U.S. pharmacy practice?
Interchangeable status means a pharmacist may substitute the biosimilar for the reference product without intervening prescriber approval when state law permits. That is a higher designation than biosimilarity alone and is why FDA highlighted the interchangeable finding for both Immgolis and Immgolis Intri in its May 2026 notice.
State automatic-substitution rules still vary. Payers may prefer the biosimilar through formulary design even before widespread pharmacy substitution. Specialty pharmacy and buy-and-bill channels for intravenous Immgolis Intri will behave differently from retail or specialty subcutaneous channels for Immgolis.
Reference-product litigation can delay launch even after FDA approval. Business development and investor models should separate regulatory approval dates from assumed first commercial availability and from peak share assumptions in rheumatoid arthritis and ulcerative colitis. Coding and reimbursement, including any temporary unclassified HCPCS use, also affect early uptake.
From a clinical-operations view, sites of care should prepare for product-name differentiation, pharmacovigilance coding to golimumab-sldi, and education that interchangeable does not mean identical inactive ingredients or device handling in every respect. Prescribing information and Medication Guides remain the governing documents for safe use.
Frequently Asked Questions
What interchangeable golimumab biosimilars did FDA approve?
FDA approved Immgolis (golimumab-sldi) as an interchangeable biosimilar to Simponi and Immgolis Intri (golimumab-sldi) as an interchangeable biosimilar to Simponi Aria. They are the first biosimilars approved for those reference products.
How are Immgolis and Immgolis Intri administered?
Immgolis is administered by subcutaneous injection in a single-dose prefilled syringe. Immgolis Intri is administered as an intravenous infusion prepared from a single-dose vial.
What evidence supported interchangeable approval?
FDA cited a comprehensive review showing the products are highly similar to their reference products with no clinically meaningful differences, including analytical comparisons across product quality attributes and a pharmacokinetic similarity study for Immgolis versus Simponi.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Simponi.
Unlock full calendar →Janssen-Cilag International N.V. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
